# Temporal dynamics of ferroptosis markers and neuroprotective intervention in cerebral ischemia-reperfusion injury: Insights for therapeutic strategy development

## TL;DR

This study explores how ferroptosis changes over time after a stroke and suggests that targeting ferroptosis could improve brain recovery.

## Contribution

The study reveals the temporal dynamics of ferroptosis markers in cerebral ischemia-reperfusion injury and identifies a potential therapeutic window.

## Key findings

- BBB disruption and altered GSH, Fe(2+), and MDA levels were observed after MCAO/R.
- Ferroptosis markers like NRF2, xCT, and GPX4 were down-regulated, while HO-1 showed an inverse trend.
- Ferrostatin-1 pretreatment protected against CIRI, unlike Erastin.

## Abstract

This study examines the temporal dynamics of ferroptosis following cerebral ischemia-reperfusion injury (CIRI) to establish a theoretical framework for innovative therapies that enhance neuronal survival by mitigating ferroptosis.

An experimental CIRI model was established in mice via middle cerebral artery occlusion and reperfusion (MCAO/R). Behavioral assessments were conducted, and blood-brain barrier (BBB) integrity was evaluated using transmission electron microscopy. Immunoblotting and ELISA were performed to determine ferroptosis dynamics post-MCAO/R. Additionally, CIRI mice received intraperitoneal injections of Ferrostain-1 (10 mg/kg/d) and Erastin (30 mg/kg/d). The effects of ferroptosis on CIRI were further verified through 2,3,5-Triphenyltetrazolium chloride and hematoxylin-eosin staining.

MCAO/R induced BBB disruption, and was associated with a reduction in GSH activity (at 1, 3, and 5 days), elevated Fe(2+) levels (at 1 day), as well as decreased MDA levels (at 3 days). Concurrently, ferroptosis markers, including NRF2, xCT, and GPX4, were significantly down-regulated on day 1, reaching their nadir by day 3, whereas HO-1 exhibited an inverse trend. Notably, Ferrostatin-1 pretreatment conferred a protective effect against CIRI, in contrast to the MCAO and Erastin groups.

This study elucidates the temporal dynamics of ferroptosis markers in the early stages of stroke, highlighting a therapeutic window for ferroptosis-related CIRI. These findings underscore the importance of targeting ferroptosis to improve neuronal survival and inform future CIRI therapies.